Earnings Call
Apr 24, 2026
Q1 FY2026
EPS Estimate
7.12
EPS Actual
7.15
Post-Earnings Close
$432.46
Earnings Reaction
-8.8%
HCA Healthcare's first quarter 2026 results were shaped by two unusual and largely offsetting forces: a sharp shortfall in seasonal respiratory volumes and an unexpected windfall from Medicaid supplemental payment programs. Respiratory-related admissions fell 42% year-over-year and ER visits dropped 32%, reflecting an abruptly mild flu season, a dynamic compounded by a January winter storm that swept through Texas, Tennessee, North Carolina, and Virginia. Together, these factors dragged an estimated $180 million from adjusted EBITDA. Partially cushioning that blow, Medicaid state supplemental programs delivered approximately $200 million in net benefit versus the prior year quarter, roughly $120 million above internal expectations, driven by the grandfathered approval of Georgia's program and the reinstatement of Texas's Atlas program. The net effect left adjusted EBITDA growth at roughly 2% year-over-year and diluted EPS, as adjusted, up approximately 11%, a result management characterized as broadly in line with the underlying business plan once temporal distortions are stripped out.
Report generated on Apr 24, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full HCA analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.